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ABBREVIATIONS

ABR

Auditory Brainstem Response

CMV

cytomegalovirus

dB (SPL)

decibels (sound pressure level)

ECMO

extracorporeal membrane oxygenation

Hz

hertz

I.P. or i.p.

intraperitoneal

JCIH

Joint Committee on Infant Hearing

kHz

kilohertz

NICU

neonatal intensive care unit

NIHL

noise-induced hearing loss

NITS

noise-induced threshold shift

OAE

otoacoustic emission

SC

subcutaneous
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“Because of improving morbidity and mortality rates for premature human infants, and,
since auditory development of humans continues into the third trimester of gestation and beyond,
premature humans subjected to the acoustically traumatic environment of high risk intensive care
nurseries and potentially ototoxic drugs administered prenatally to the mother or postnatally to
the infant himself/herself may be prone to develop long-term pathological sequelae.”
~C.M. Henley and L.P. Rybak, 1995
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According to the Centers for Disease Control and Prevention (CDC), the estimated
incidence of hearing loss in infants is approximately one to three per one-thousand live births
(National Center on Birth Defects and Developmental Disabilities, 2007). Though this number
represents hearing loss that is congenital, events that occur in the early part of an infant’s life
may result in the acquisition of hearing loss. According to the Joint Committee on Infant
Hearing (JCIH, 2007), the following are risk factors associated with congenital, acquired, and
progressive hearing loss in childhood: family history, neonatal intensive care unit (NICU) stay
for more than five days, extracorporeal membrane oxygenation (ECMO), assisted ventilation,
exposure to ototoxic medications or loop diuretics, hyperbilirubinemia, in utero infections
(CMV, herpes, rubella), craniofacial anomalies, syndromes associated with hearing loss and
syndromic stigmata, neurodegenerative disorders, postnatal infections (meningitis), head trauma,
and chemotherapy. One potential risk factor for acquired hearing loss that has been underinvestigated and is not included in the JCIH report is neonatal noise exposure.
On a daily basis, medically fragile neonates are transported between medical centers via
ambulance and aircraft. Many of these infants are premature, are receiving or have received
ototoxic antibiotics, and their unprotected ears are commonly exposed to high levels of noise.
Although these “once in a lifetime” exposures are usually of relatively short duration and may
not pose a risk of hearing loss in neonates by themselves, the potential interactions of these noise
exposures in conjunction with other agents (i.e., ototoxic antibiotics, other risk factors) has been
underexplored. Several investigators have recorded sound levels in neonatal transit with peaks
of up to 125 dB SPL (Skeoch, Jackson, Wilson, & Booth, 2005) and 103 dBA (Shenai, 1977).
Although an Australian study reported average sound levels of approximately 82 dBA during
helicopter transport (Buckland et al., 2003), a study at Washington University found that infants
5
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were commonly exposed to sounds of 90-100 dBA, and some were as high as 115 dBA during
helicopter transport to St. Louis Children’s Hospital (Weathers, in press).
Aminoglycoside antibiotics, which are used to treat diseases such as tuberculosis and
gram-negative infections (i.e., pneumonia) in humans, are known to result in ototoxicity,
vestibulotoxicity, and nephrotoxicity. Studies in the early 1980s indicated that premature infants
were more susceptible to aminoglycoside ototoxicity than were adults (as cited in Henley and
Rybak, 1995). Aminoglycoside antibiotic treatment in newborn infants ranges in dosage from 5
to 400 mg/kg/day, depending on the drug and the bodyweight and age of the infant. Kanamycin,
for example, has a recommended dosage of 15-20 mg/kg/day for infants less than one week of
age (Thompson, 1983). These antibiotics are usually administered intravenously or
intramuscularly and are divided into two or three equal daily doses. For serious infections, such
as bacterial meningitis, aminoglycoside antibiotic treatment may last in excess of three weeks
(Finitzo-Hieber, McCracken, Roeser, Allen, Chrane, & Morrow, 1979). One additional factor
that many of these infants have in common is the administration of supplemental oxygen.
Excessive oxygen administration resulting in oxygen toxicity in humans is known to cause
damage to many body systems (Spitzer, 2005). The synergistic affect that oxygen in small
amounts, such as for maintenance before and after helicopter transfer, may play in noise-induced
hearing loss is unclear. Though some animal studies have shown that oxygen therapy may help
to reduce hearing loss associated with acoustic trauma (Ward, 1995 and Fakhry, Rostain, &
Cazals, 2007), others have indicated that immediate hyperbaric oxygen therapy may increase
hearing loss related to acoustic trauma (Cakir, Ercan, Civelek, Korpinar, Toklu, Gedik, Isik,
Sayin, & Turgut, 2006).
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Each of the aforementioned conditions, prematurity, aminoglycoside antibiotic treatment,
noise exposure, and oxygen therapy, are potential risk factors for hearing loss in and of
themselves. We have hypothesized that the combined effects of ototoxic antibiotics, noise,
and/or hyperoxia will result in an even greater risk for hearing loss in premature neonates.
Ideally, a study to assess such a correlation would record auditory brainstem response (ABR)
thresholds and/or otoacoustic emissions (OAEs) in infants both before and after exposure to the
aforementioned conditions. Because it is unethical to knowingly expose humans to such
potentially damaging agents and events, an animal model is a logical substitution.
The laboratory mouse is a well-established model for human auditory conditions, as it
possesses strikingly similar cochlear anatomy and physiology and displays similar patterns of
age-related, noise-induced, and ototoxicity-related hearing loss. In addition, the short life span
of the mouse allows for easy study of auditory conditions both during early critical periods and
throughout the life span (Henry & McGinn, 1992). The CBA/J inbred stain of mice has been
widely used as a model of normal hearing and was selected as the model in the present study.
Unlike humans, who have an audible frequency range of about 20 to 20,000 Hz, mice hear
frequencies from 2 to 100 kHz, with greatest sensitivity between 12 to 24 kHz (as cited in Zheng,
Johnson, & Erway, 1999). The auditory system of CBA/J mice remains normal until near the
end of its life span, which allows for a more accurate study of ototraumatic manifestations on the
normal auditory system.
It is known that young mice are more susceptible to ototoxic and ototraumatic events than
are older mice. The first study to assess the susceptibility to noise-induced hearing loss (NIHL)
across the entire lifespan of the mouse was completed in 1983 by Kenneth R. Henry. Henry
exposed 369 CBA/J mice at various ages to five minutes of an octave band white noise (12-24
7
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kHz) at 124, 114, or 110 dB SPL. Using electrocochleography, Henry assessed auditory nerve
function at four days post-exposure. Older mice (≥37 days) underwent pre-exposure testing,
whereas younger animals (<37 days) were compared to littermate controls. The major findings
were as follows: susceptibility begins at approximately 16 days of age, overall susceptibility was
greatest from 20 to 90 days of age, during which time the center frequency demonstrates the
greatest threshold shift, and during adulthood (≥ 120 days) a threshold shift is only observed at
the highest frequencies (p. 378). Henry concluded that “the CBA/J mouse does not have a
sharply defined critical period for NITS, even though the young animal is most severely
affected” (p. 381). A more recent noise dose-response study by Ohlemiller, Wright, and
Heidbreder (2000) found that CBA/CaJ, C57BL/6J, and BALB/cJ mice aged 1 to 2 months were
more susceptible to NIHL than were mice aged 5 to 7 months. The aforementioned study
exposed animals to different durations of broadband noise (4-45 kHz) at 110 dB SPL and
assessed the amount of ABR threshold shift at two weeks post-exposure. A large proportion of
young CBA/CaJ mice had permanent threshold shifts at approximately 3.42 minutes of noise
exposure, whereas 63 minutes of noise exposure were required for an equivalent proportion of
older CBA/CaJ mice to exhibit permanent threshold shifts.
As with noise exposure, the susceptibility of the mouse to ototoxicity is age-dependent,
with the young mouse having the greatest degree of susceptibility. Unlike susceptibility to noise
trauma however, the susceptibility to ototoxic drugs does not continue throughout the lifespan of
the mouse. A 1983 study by Chen and Saunders sought to establish the critical period for
kanamycin ototoxicity in mice. A previous study (Chen & Aberdeen, 1981) had indirectly
suggested that the critical period for kanamycin ototoxicity in mice was likely 10 to 14 days of
age, as this was the time period during which administration of kanamycin resulted in
8
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susceptibility to audiogenic seizures in BALB/c mice (as cited in Chen & Saunders, 1983).
Using the C57BL/6J strain, Chen and Saunders injected mice aged 6-9, 10-13, or 15-18 days
with a once daily dose of kanamycin (400 mg/kg, i.p.) or an equivalent volume of saline for four
days. At 15 days post-injection regimen, the animals were sacrificed and cochleae were
harvested for morphologic analysis. This study supported the previous assumption made by
Chen and Aberdeen, as it was discovered that only mice aged 10 to 13 days had significant
damage to the outer hair cells, whereas younger and older mice showed little to no structural
damage. The investigators also suggested that this period coincides with the rapid period of
cochlear development and that age, strain, and duration of treatment may be important factors in
the ototoxicity of kanamycin. It is important to note that morphological analysis of ototoxicity in
such a case is a more appropriate assessment tool than electrophysiologic responses (such as the
ABR) since the auditory system of the mouse is functionally immature until approximately 18
days of age (Henry, 1983).
Finally, it has been established that noise paired with kanamycin results in a greater
degree of hearing loss than either factor alone (Dayal, et al., 1971; Quante, 1973; Dayal & Barek,
1975; Marques et al., 1975; Hawkins et al., 1975; Ryan & Bone, 1978; Brown et al., 1980;
Brummett, Fox, & Kempton, 1992 (as cited in Humes, 1984)). An example of one such study by
Brummett and colleagues (1992) identified a synergistic effect between subclinical doses of
white noise (as low as 75 dBA) and subclinical doses of kanamycin (300 mg/kg) on the amount
of hair cell loss in adult guinea pigs. All of the aforementioned studies used adult animals, with
the overwhelming majority using the guinea pig as a model. In a review paper by Humes (1984),
it was suggested that future research “explore the potential interactions resulting from concurrent
exposure to multiple agents…in younger, more susceptible animals” (p. 1318).
9
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The current study tested the following hypotheses in an effort to explore such interactions
in younger mice: (a) noise exposure following kanamycin treatment will result in an increase in
ABR thresholds relative to ABR thresholds in mice exposed to noise alone or kanamycin alone,
(b) exposure to 100% oxygen before and after a noise exposure will result in an increase in ABR
thresholds relative to those in mice exposed to noise alone, and (c) combined exposures to
kanamycin, noise, and hyperoxia will result in an increase in ABR thresholds relative to those in
other treatment groups.
MATERIALS AND METHODS
Animals
A total of 27 male and 23 female post-weanling CBA/J mice were utilized. Mice were
bred from in-house dam:sire breeding pairs and were housed in the Mechanisms of Cochlear
Injury Laboratory at Washington University School of Medicine throughout the experiment. A
few of the animals were obtained directly from The Jackson Laboratory. Mice were assigned to
one of six groups: control, noise alone, kanamycin alone, kanamycin plus noise, hyperoxia plus
noise, and kanamycin plus hyperoxia plus noise. All procedures were approved by the Animal
Studies Committee at Washington University School of Medicine. The following table
summarizes the number and sex of mice per group:
GROUP
CONTROL
KANAMYCIN
NOISE
KANAMYCIN + NOISE
HYPEROXIA + NOISE
KANAMYCIN + HYPEROXIA + NOISE

N
9
9
9
8
8
7

Table 1. Numbers of animals per group and by sex
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MALE
4
5
6
4
5
3

FEMALE
5
4
3
4
3
4
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Kanamycin
Mice in groups receiving kanamycin were injected subcutaneously twice daily for ten or
eleven days with a 300 mg/kg solution (63.93 mg/mL concentration). Injections began at
approximately 20 days post-gestational age and were stopped at approximately 29 or 30 days
post-gestational age. Mice were weighed prior to each injection and received 0.006 cc of drug
for every gram of body weight. Injections occurred at approximately twelve hour intervals in an
attempt to maintain a chronic drug state. The drug regimen was well-tolerated as no mice were
lost during the course of treatment.
Noise Exposure
At 30 days post-gestational age, mice in a noise treatment group were exposed to 30
seconds of broadband noise (4 to 45 kHz) at approximately 110 dB SPL. Noise was produced
and filtered with General Radio 1310 generators and Krohn-Hite 3550 filters, respectively.
Groups of two to three animals were placed in a wired cage suspended between four speakers at
0, 90, 180, and 360 degrees azimuth in a single-walled sound-proof booth with foam treatment
(Industrial Acoustics, Bronx, NY). The cage was rotated at approximately 0.013 Hz throughout
the duration of the exposure in order to achieve as consistent an exposure as possible. No
attempt was made to provide food or water throughout the exposure. For mice receiving
exposure to kanamycin and noise, the noise exposure was initiated at 15 minutes following the
final dose of kanamycin (injection day 11). A pharmacokinetic analysis of subcutaneous
kanamycin injections in adult mice by Sinswat and colleagues (2000) found a peak serum level
of approximately 15 minutes and an elimination half-life of one hour (as cited in Wu, Sha,
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McLaren, Kawamoto, Raphael, & Schacht, 2001, p. 174), thus the rationale for a 15 minute postinjection noise exposure regimen.
Hyperoxia
Hyperoxic conditions were achieved using an oxygen tank coupled to a modified plastic
storage container. Up to six mice at a time were placed in the container and were exposed to
100% oxygen for a total of six hours (three hours pre- and post-noise exposure) at normal
atmospheric pressure. No attempt was made to provide food or water during exposures.
ABR Recordings
ABR recording occurred between nine and eleven days post-treatment, or at
approximately 39 to 41 days post-gestational age. Tucker-Davis Technologies (TDT) System II
hardware and BioSig 33 software were used. Calibration occurred prior to any recordings.
Animals were anesthetized with a solution of ketamine and xylazine (80/15 mg/kg, i.p.).
Subdermal needle electrodes were placed in the mid-back (ground), medial to the right pinna
(active), and at the vertex (reference). Body temperature and heart rate were monitored
throughout testing using a rectal probe, and body temperature was maintained at 37.5 ± 1.0°C
using an isothermal pad. The right ear of each mouse was stimulated with 5 msec tonebursts
(1000 repetitions, 20/second, 1.0 msec rise time) at frequencies of 5, 10, 20, 28.3, and 40 kHz.
Filter settings were 100 to 10,000 Hz and speaker distance was 7 cm.
The first wave of the ABR is thought to be generated by cochlear and early auditory
nerve activity and is the most robust wave of the mouse ABR (Zheng et al., 1999). Therefore,
thresholds were observed as the lowest level that the first negative peak (wave I) could be
identified using the following bracketing technique: increase attenuation 10 dB following a
12
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positive response and decrease attenuation 5 dB following a negative response. Following ABR
recording, mice were sacrificed and cochleae were harvested for morphologic analysis from a
number of the animals in the study. Anesthesia for ABR recording was well-tolerated, as no
animals were lost as a result.
RESULTS
Preliminary noise exposures in the current study were four minutes in duration, which
was derived from CBA/CaJ data from the previously mentioned noise dose-response
investigation by Ohlemiller et al. (2000), as the CBA/J and CBA/CaJ strains of mice are often
used interchangeably in research. In the current study,
CBA/J mice appear to be markedly more susceptible to

CBA/J current study

NIHL than CBA/CaJ mice. The noise dose-response
plot for young CBA/CaJ mice from the Ohlemiller
(2000) study can be seen in the top portion of Figure 1.
The orange triangles indicate the initial noise doseresponse findings for young CBA/J mice in the current
study. These results suggest that young CBA/J mice are
incredibly more susceptible to noise induced hearing
loss than CBA/CaJ mice, as noise exposures of 4, 3, 2,
and 0.5 minutes resulted in 100% of the mice having a

Figure 1. Young CBA/J are markedly more
susceptible to NIHL than young CBA/CaJ
mice
Reprinted with permission from
Ohlemiller et al., 2001

large amount of hearing loss.
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A two-way analysis of variance (ANOVA) was used to determine if a statistical
difference in thresholds existed between groups. The following table provides average
thresholds per frequency per group with standard deviations in parentheses:
GROUP

5 kHz

10 kHz

20 kHz

28.3 kHz

40 kHz

CONTROL

41.44
(4.64)

23.56
(4.64)

31.67
(7.91)

32.11
(6.51)

38.33
(8.29)

KANAMYCIN

39.22
(3.63)

22.44
(1.67)

25.56
(3.00)

31
(5.00)

36.25
(9.71)

NOISE

68.11
(18.67)

58.56
(20.07)

64.44
(24.30)

73.78
(27.05)

90
(22.91)

KANAMYCIN + NOISE

42.63
(6.23)

22.38
(4.17)

30.63
(4.96)

34.13
(4.58)

53.13
(19.45)

HYPEROXIA + NOISE

53.25
(14.58)

43.63
(16.57)

61.88
(20.34)

81.63
(16.13)

91.25
(21.00)

KANAMYCIN + HYPEROXIA
+ NOISE

37.71
(6.73)

18.71
(1.89)

27.86
(5.67)

28.14
(4.88)

40.71
(13.67)

Table 2. Average thresholds per group with standard deviations in parentheses

No difference was observed between the
120

Control, Kanamycin, Kanamycin + Noise,
and Kanamycin + Hyperoxia + Noise

control group and the kanamycin alone group,

Control
KM
KM + N
KM N HO

100

Threshold (dB SPL)

kanamycin plus noise group, or the kanamycin
plus hyperoxia plus noise group as can be seen
in Figure 2. Little variability was found

80

60

40

between the mice in each of these groups. The
20

thresholds of the noise alone and hyperoxia plus

0
5.0

noise were significantly different from the

10.0

20.0

28.3

40.0

Frequency (kHz)

control group (p<0.001). On average, the noise alone

14

Figure 2. Average thresholds for control, kanamycin,
kanamycin +noise, and kanamycin + hyperoxia + noise
groups with error bars
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group had approximately 35 to 40 dB poorer thresholds than the control group. No significant
difference was found between the noise alone group and the hyperoxia plus noise group
(p=0.303) as can be seen in Figure 3. Both the noise alone and the hyperoxia plus noise groups
had a great degree of variability between mice at all frequencies.

Control, Noise Alone, and Hyperoxia + Noise

Noise vs. Kanamycin + Noise
120

120

Noise

100

Threshold (dB SPL)

100

Threshold (dB SPL)

Control

Noise
Control
HO+N

80

60

40

KM + N

80

60

40

20

20

0

0
5.0

10.0

20.0

28.8

5.0

40.0

10.0

20.0

28.3

40.0

Frequency (kHz)

Frequency (kHz)

Figure 3. Average thresholds for control, noise
alone, and hyperoxia + noise groups. There is a
significant difference between the two experimental
groups and the control group.

Figure 4. Average thresholds for control, noise, and
kanamycin + noise.

DISCUSSION
The purpose of the current study was to determine if a combined exposure to kanamycin,
noise, and oxygen would result in a synergistic effect on ABR thresholds in young CBA/J mice.
It was hypothesized that (a) noise exposure following kanamycin treatment will result in an
increase in ABR thresholds relative to those in mice exposed to noise alone or kanamycin alone,
(b) exposure to 100% oxygen before and after a noise exposure will result in an increase in ABR
thresholds relative to those in mice exposed to noise alone, and (c) combined exposures to
kanamycin, noise, and hyperoxia will result in an increase in ABR thresholds relative to those in
other treatment groups. Neither the hypothesis that noise plus kanamycin would result in a
15
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synergistic effect on ABR thresholds nor the hypothesis that kanamycin plus oxygen plus noise
would result in a synergistic effect on ABR thresholds was found to be true. In fact, kanamycin
not only resulted in a protective affect against noise exposure in these groups, but its
administration actually seemed to prevent NIHL completely as can be seen in Figure 4. To the
author’s knowledge, no other study has shown kanamycin to have such an effect. Also, the
addition of oxygen was found to have no significant effect on ABR thresholds in noise-exposed
animals (p=0.303).
The possibility exists that the protective effect of kanamycin against NIHL is an artifact,
and that, in fact, the stress of handling and injecting the mice over 10 or 11 days time is
preconditioning the animals against NIHL. Preconditioning refers to an early event that is
thought to be mildly injurious initiating protection against a later, more injurious event. A wide
body of research exists on preconditioning against NIHL in mice and indicates that factors
including heat stress, restraint, and hypoxia result in a cochlear preconditioning against noise
exposure (Gagnon, Simmons, Bao, Lei, Ortmann, & Ohlemiller, 2007). This cochlear
preconditioning is thought to engage some innate protective cascades, in which factors such as
improved blood flow, increased glucocorticoid stress hormones, and heat shock proteins play a
role in this protection.
In order to determine if the protective effect of kanamycin is real or is in fact a
manifestation of some sort of cochlear preconditioning, several control groups should be added
to the current study. One such necessary control group would receive subcutaneous saline
injections for eleven days followed by noise exposure to control for the stress of handling. A
kanamycin injection control group (11 days of kanamycin followed by ABR testing) would also
be required in order to verify that acute hearing loss did not exist from the kanamycin at the time
16
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of noise exposure. Finally, a group receiving a single kanamycin injection followed by a single
noise exposure would also be necessary to evaluate the effectiveness of kanamycin of protecting
against NIHL in a single dose. To date, two mice have received this treatment (1 kanamycin
injection, 300 mg/kg, i.p. followed by 30 sec. noise exposure 15 min. later) and hearing loss was
apparent. This finding suggests that the mere presence of kanamycin prior to a noise exposure is
not sufficient be protective against NIHL.
It is unclear how the findings of the current study relate to human neonates. If in fact
kanamycin proves to be protective against NIHL, further studies need to be done to address
variables such as kanamycin dosing, the levels and duration of noise for which the protective
effect remains, and the level of protection in older mice. According to Rybak and Ramkumar
(2007), “aminoglycosides persist in the inner ear tissues for 6 months or longer after
administration” (p. 932); therefore, it would be of interest to determine the intervals between
kanamycin exposure and noise in which the protective effect remains. In addition, the
physiological mechanisms of such a protective effect would need to be explored. Finally, future
research should address the apparent increased susceptibility to NIHL in young CBA/J mice by
performing a noise dose-response study.
In conclusion, much is unknown about the mysterious auditory system. With so many
pharmaceutical options for preventing and treating disease and other medical conditions of many
of the body systems, it seems likely that something must exist that can protect the auditory
system from the damaging effects of noise. How incredible to think that something as simple as
kanamycin, typically considered an ototoxic drug, may in fact hold the key to the prevention of
noise-induced hearing loss?
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APPENDIX A. Mean thresholds by group
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